dendritic cells GSK-3 mediates differentiation and activation of proinflammatory

[1]  T. Luft,et al.  Adaptive functional differentiation of dendritic cells: integrating the network of extra- and intracellular signals. , 2006, Blood.

[2]  S. Foster,et al.  Insulin reduces the multiple organ injury and dysfunction caused by coadministration of lipopolysaccharide and peptidoglycan independently of blood glucose: Role of glycogen synthase kinase-3&bgr; inhibition* , 2006, Critical care medicine.

[3]  F. Tacke,et al.  Modulation of Dendritic Cell Trafficking to and from the Airways , 2006, The Journal of Immunology.

[4]  G. Trinchieri,et al.  Dendritic cell-NK cell cross-talk: regulation and physiopathology. , 2006, Current topics in microbiology and immunology.

[5]  M. Boes,et al.  T cell priming by tissue-derived dendritic cells: new insights from recent murine studies. , 2005, Cellular immunology.

[6]  S. Foster,et al.  GSK-3β inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat* , 2005, Critical care medicine.

[7]  R. Jope,et al.  Toll-like receptor–mediated cytokine production is differentially regulated by glycogen synthase kinase 3 , 2005, Nature Immunology.

[8]  R. Urrutia,et al.  Glycogen Synthase Kinase-3β Participates in Nuclear Factor κB–Mediated Gene Transcription and Cell Survival in Pancreatic Cancer Cells , 2005 .

[9]  G. Christodoulou,et al.  Cytokine production in bipolar affective disorder patients under lithium treatment. , 2004, Journal of affective disorders.

[10]  J. Waxman,et al.  Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth , 2004, Oncogene.

[11]  M. Görner,et al.  Tuning the volume of the immune response: strength and persistence of stimulation determine migration and cytokine secretion of dendritic cells. , 2004, Blood.

[12]  Kirk W. Johnson,et al.  Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. , 2004, Current pharmaceutical design.

[13]  R. Jope,et al.  The glamour and gloom of glycogen synthase kinase-3. , 2004, Trends in biochemical sciences.

[14]  M. Karayiorgou,et al.  Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia , 2004, Nature Genetics.

[15]  A. Serretti,et al.  A single nucleotide polymorphism in glycogen synthase kinase 3-β promoter gene influences onset of illness in patients affected by bipolar disorder , 2004, Neuroscience Letters.

[16]  H. Manji,et al.  Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. , 2004 .

[17]  G. Randolph,et al.  Factors and signals that govern the migration of dendritic cells via lymphatics: recent advances , 2004, Springer Seminars in Immunopathology.

[18]  J. Woodgett,et al.  Physiological roles of glycogen synthase kinase-3: potential as a therapeutic target for diabetes and other disorders. , 2003, Current drug targets. Immune, endocrine and metabolic disorders.

[19]  Zhaoyi Wang,et al.  Inhibition of breast cancer cell growth by the Wilms' tumor suppressor WT1 is associated with a destabilization of beta-catenin. , 2003, Anticancer research.

[20]  B. Doble,et al.  GSK-3: tricks of the trade for a multi-tasking kinase , 2003, Journal of Cell Science.

[21]  E. Smeraldi,et al.  Interleukine-6 serum levels correlate with response to antidepressant sleep deprivation and sleep phase advance , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[22]  R. Bhat,et al.  GSK3β Signalling: Casting a Wide Net in Alzheimer’s Disease , 2002, Neurosignals.

[23]  T. Luft,et al.  Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. , 2002, Blood.

[24]  J. Licinio,et al.  The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs , 2002, Molecular Psychiatry.

[25]  P. Cohen,et al.  GSK3 takes centre stage more than 20 years after its discovery. , 2001, The Biochemical journal.

[26]  H. Manji,et al.  The effects of lithium on ex vivo cytokine production , 2001, Biological Psychiatry.

[27]  P. Cohen,et al.  A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. , 2001, Molecular Cell.

[28]  A. Harwood,et al.  Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. , 2001, Biochemical and biophysical research communications.

[29]  Kenji F. Tanaka,et al.  Serum interleukin-18 levels are elevated in schizophrenia , 2000, Psychiatry Research.

[30]  J. Levine,et al.  Cerebrospinal Cytokine Levels in Patients with Acute Depression , 1999, Neuropsychobiology.

[31]  P. Cohen,et al.  A GSK3‐binding peptide from FRAT1 selectively inhibits the GSK3‐catalysed phosphorylation of Axin and β‐catenin , 1999, FEBS letters.

[32]  D. Chuang,et al.  Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[33]  P. Whybrow,et al.  Immune parameters in rapid cycling bipolar patients before and after lithium treatment. , 1999, Journal of psychiatric research.

[34]  Akira Kikuchi,et al.  Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK‐3β and β‐catenin and promotes GSK‐3β‐dependent phosphorylation of β‐catenin , 1998 .

[35]  Philip R. Cohen,et al.  Further evidence that the inhibition of glycogen synthase kinase‐3β by IGF‐1 is mediated by PDK1/PKB‐induced phosphorylation of Ser‐9 and not by dephosphorylation of Tyr‐216 , 1997, FEBS letters.

[36]  P. Cohen,et al.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B , 1995, Nature.

[37]  J. Woodgett,et al.  Modulation of the glycogen synthase kinase‐3 family by tyrosine phosphorylation. , 1993, The EMBO journal.